Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line
CHG‐IPA showed no clear difference in premature central line removal, defined as number of central venous… compared with CHG‐A (moderate certainty).
1 finding from 1 review
Central line‐associated bloodstream infection (CLABSI) expressed using absolute rates of infants · neonates that require central line
It is very uncertain whether CHG‐IPA changes central line‐associated bloodstream infection (CLABSI) expressed… compared with PI (very low certainty).
1 finding from 1 review
Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line
CHG‐IPA showed no clear difference in proven catheter‐related bloodstream infection (CRBSI) expressed by… compared with CHG‐A (low certainty).
1 finding from 1 review
Central‐line associated bloodstream infection (CLABSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line
CHG‐IPA showed no clear difference in central‐line associated bloodstream infection (CLABSI) expressed by… compared with CHG‐A (low certainty).
1 finding from 1 review
Response to treatment at 8 weeks · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher response to treatment at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to any cause at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects (dropouts) · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Remission · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher remission rates at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: akathisia (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Weight gain · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Positive‐pressure ventilation after institution of treatment · treatment of apnea
It is very uncertain whether doxapram changes 2a. Need for positive pressure ventilation after initiation of… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
3 findings from 1 review
Treatment failure · preterm infants receiving nasal CPAP
Bubble may leads to lower treatment failure compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants receiving nasal CPAP
Bubble showed no clear difference in all‐cause mortality before hospital discharge compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm infants receiving nasal CPAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pneumothorax · preterm infants receiving nasal CPAP
Bubble showed no clear difference in pneumothorax compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Moderate‐severe nasal injury · preterm infants receiving nasal CPAP
Bubble probably leads to higher moderate‐severe nasal injury compared with ventilator or Infant Flow Driver nasal continuous positive airway… (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
Bubble showed no clear difference in bronchopulmonary dysplasia compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Malaria parasite prevalence · people living in malaria‐endemic areas
Topical repellents may leads to lower malaria prevalence ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
MMP-9 expression/activity · Human ex vivo carious dentin under sealed cavities
MMP-9 shows no difference before vs after cavity sealing; the evidence is very uncertain (very low certainty).
1 finding from 1 review